ES2175901T3 - Benzoimidazoles como inhibidores de la cilooxigenasa-2. - Google Patents

Benzoimidazoles como inhibidores de la cilooxigenasa-2.

Info

Publication number
ES2175901T3
ES2175901T3 ES99300824T ES99300824T ES2175901T3 ES 2175901 T3 ES2175901 T3 ES 2175901T3 ES 99300824 T ES99300824 T ES 99300824T ES 99300824 T ES99300824 T ES 99300824T ES 2175901 T3 ES2175901 T3 ES 2175901T3
Authority
ES
Spain
Prior art keywords
rent
independently
heteroarile
analogs
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99300824T
Other languages
English (en)
Inventor
Yoshiyuki Okumura
Yoshinori Murata
Takashi Mano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2175901T3 publication Critical patent/ES2175901T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

EN ESTA INVENCION SE PRESENTA UN COMPUESTO DE LA FORMULA SIGUIENTE: O LAS SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO, EN LA QUE AR ES HETEROARILO; X 1 Y X 2 SE SELECCIONAN, INDEPENDIENTEMENTE, DE HALO, ALQUILO C 1 - C 4 , H IDROXI, ALCOXI C 1 - C 4 , AMINO, ALCANOILO C 1 - C 4 , CARBOXI, CARBAMILO, CIANO, NITRO, MERCAPTO, (ALQUIL)TIO C 1 - C 4 , (ALQUIL)SULFINILO C 1 C 4 , (ALQUIL)SULFONILO C 1 - C 4 , AMINOSULFONILO, O ANALOGOS; R 1 SE SELECCIONA DEL HIDROGENO, ALQUILO C 1 C 4 LINEAL O RAMIFICADO, CICLOALQUILO C 3 - C 8 , CICLOALQUENILO C 4 C 8 , FENILO, HETEROARILO Y SIMILARES; R 2 Y R 3 SE SELECCIONAN, INDEPENDIENTEMENTE, DEL HIDROGENO, HALO, ALQUILO C 1 - C 4 , FENILO Y ANALOGOS; O R 1 Y R 2 PUEDEN FORMAR, JUNTO CON EL ATOMO DE CARBONO AL QUE ESTAN ENLAZADOS, UN ANILLO DE CICLOALQUILO C5 C 7 ; Y M Y N SON, INDEPENDIENTEMENTE, 0, 1, 2 O 3. ESTOS COMPUESTOS Y LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN TALES COMPUESTOS SON UTILES COMO AGENTES ANALGESICOS Y ANTIINFLAMATORIOS.
ES99300824T 1998-02-11 1999-02-04 Benzoimidazoles como inhibidores de la cilooxigenasa-2. Expired - Lifetime ES2175901T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB9800164 1998-02-11
US09/244,875 US6310079B1 (en) 1998-02-11 1999-02-05 Benzimidazole cyclooxygenase-2 inhibitors

Publications (1)

Publication Number Publication Date
ES2175901T3 true ES2175901T3 (es) 2002-11-16

Family

ID=26318715

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99300824T Expired - Lifetime ES2175901T3 (es) 1998-02-11 1999-02-04 Benzoimidazoles como inhibidores de la cilooxigenasa-2.

Country Status (10)

Country Link
US (3) US6310079B1 (es)
EP (1) EP0937722B1 (es)
JP (1) JP3256513B2 (es)
AT (1) ATE220066T1 (es)
BR (1) BR9900565A (es)
CA (1) CA2261426C (es)
DE (1) DE69901969T2 (es)
DK (1) DK0937722T3 (es)
ES (1) ES2175901T3 (es)
PT (1) PT937722E (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
JP3256513B2 (ja) * 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
WO2002000257A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for alzheimer's disease
WO2002000255A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for cancer
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
BR0313160A (pt) * 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
ES2341240T3 (es) 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
ATE342722T1 (de) 2003-05-07 2006-11-15 Osteologix As Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
DK1622630T3 (da) 2003-05-07 2012-12-17 Osteologix As P009368epdk1
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
EP1708718A1 (en) 2004-01-22 2006-10-11 Pfizer Limited Triazole derivatives which inhibit vasopressin antagonistic activity
JP2007519720A (ja) 2004-01-28 2007-07-19 スミスクライン ビーチャム コーポレーション チアゾール化合物
CA2563963A1 (en) * 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
AU2005296305A1 (en) * 2004-10-12 2006-04-27 Decode Genetics Ehf Sulfonamide peri-substituted bicyclics for occlusive artery disease
US7442716B2 (en) * 2004-12-17 2008-10-28 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
AU2005316091B2 (en) * 2004-12-17 2011-12-01 Merck Canada Inc. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-D]imidazoles as mPGES-1 inhibitors
US20060251702A1 (en) * 2005-05-05 2006-11-09 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
AU2007230911A1 (en) * 2006-03-23 2007-10-04 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
EP2019675A4 (en) * 2006-05-02 2011-03-02 Merck Frosst Canada Ltd METHOD FOR THE TREATMENT OR PREVENTION OF NEOPLASIA
PT2799427T (pt) 2006-07-05 2018-10-16 Fibrotech Therapeutics Pty Ltd Compostos terapêuticos
UA94979C2 (uk) 2006-12-22 2011-06-25 Рекордати Айеленд Лимитед КОМБІНОВАНА ТЕРАПІЯ ПОРУШЕНЬ НИЖНІХ СЕЧОВИВІДНИХ ШЛЯХІВ ЛІГАНДАМИ α2δ І НПЗП
WO2010012745A2 (en) * 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh Benzimidazoles
IN2012DN03312A (es) 2009-10-22 2015-10-23 Fibrotech Therapeutics Pty Ltd
US11583516B2 (en) 2016-09-07 2023-02-21 Trustees Of Tufts College Dash inhibitors, and uses related thereto
EP3577103A1 (en) 2017-02-03 2019-12-11 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
EP3735472A4 (en) * 2018-01-07 2021-10-27 Nucleix Ltd. KITS AND METHODS FOR DETECTING CANCER MUTATIONS
US20240165148A1 (en) 2021-03-15 2024-05-23 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
KR102853258B1 (ko) * 2023-06-20 2025-09-01 이원다이애그노믹스(주) 암의 예방, 치료 또는 개선에 유효한 효과를 나타내는 신규한 화합물, 이의 제조방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5013795B2 (es) 1972-12-12 1975-05-22
JPS5975257A (ja) 1982-10-23 1984-04-27 Ricoh Co Ltd 電子写真用感光体
GB8307865D0 (en) * 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US4812460A (en) * 1986-03-25 1989-03-14 Boehringer Ingelheim Pharmaceutical, Inc. 3-[2-(3',5'-di-t-butyl-4'-hydroxyphenyl)ethenyl]pyridine
JPH06759B2 (ja) * 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
JPH03219232A (ja) 1990-01-24 1991-09-26 Konica Corp 分光増感されたハロゲン化銀写真感光材料
JPH06194780A (ja) 1992-12-24 1994-07-15 Konica Corp ハロゲン化銀写真乳剤
JP3219232B2 (ja) 1995-08-14 2001-10-15 シャープ株式会社 液晶表示装置
DK0846689T3 (da) * 1996-12-09 2004-04-19 Pfizer Benzimidazolforbindelser
AU6221998A (en) 1997-02-13 1998-09-08 Glaxo Group Limited Benzimidazole derivatives
JP3256513B2 (ja) 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤

Also Published As

Publication number Publication date
EP0937722A1 (en) 1999-08-25
DE69901969D1 (de) 2002-08-08
DK0937722T3 (da) 2002-07-22
US6310079B1 (en) 2001-10-30
PT937722E (pt) 2002-10-31
CA2261426C (en) 2002-09-24
US6713482B2 (en) 2004-03-30
US20030013886A1 (en) 2003-01-16
JP3256513B2 (ja) 2002-02-12
CA2261426A1 (en) 1999-08-11
DE69901969T2 (de) 2002-10-24
JPH11263788A (ja) 1999-09-28
US20040181062A1 (en) 2004-09-16
EP0937722B1 (en) 2002-07-03
ATE220066T1 (de) 2002-07-15
BR9900565A (pt) 2000-05-02

Similar Documents

Publication Publication Date Title
ES2175901T3 (es) Benzoimidazoles como inhibidores de la cilooxigenasa-2.
SV2003000876A (es) Quinazolinas como inhibidores de mmp-13
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
PE20050130A1 (es) Compuestos organicos
PA8538401A1 (es) Pirimidinas inhibidoras de metaloproteinasas de matriz
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
AR087046A2 (es) Compuestos derivados de 4-oxoquinolina
ES2172575T3 (es) Composicion bactericida.
PE20080093A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
HUP0301391A2 (hu) Piperazin- és piperidinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0002476A2 (hu) Aminvegyületek, előállításuk és alkalmazásuk
NO20026094L (no) Kondenserte azepinderivater og deres anvendelse som antidiuretiske midler
PA8466201A1 (es) Compuestos de indol 2,3-sustituidos como agentes antiinflamatorios y analgesicos
DE69513219D1 (de) Kondensierte heterocyclische Verbindungen, ihre Herstellung und Anwendung
EA200300531A1 (ru) Производные фталазинона
CY1110904T1 (el) Φαρμακευτικως ενεργα παραγωγα βενζοσουλφοναμιδιου ως αναστολεις πρωτεϊνικων κινασων jun
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
PA8475401A1 (es) Compuestos de sulfonilbenceno como agentes antiinflamatorios/analgesicos
ATE277897T1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
BR0314591A (pt) Métodos de aumento de plaquetas e produção de célula tronco hematopoiética
ES2163239T3 (es) Nuevos derivados cromenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
EE04496B1 (et) Tetrahüdro-gamma-karboliinid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad kompositsioonid
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
AR005532A1 (es) Compuestos de dihalopropeno, las composiciones insecticidas/acaricidas que los contienen y los intermediarios de sintesis de dichos compuestos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 937722

Country of ref document: ES